Physician profile
Jonathan Velez Rivera
NPI 1033524707
$24,040.22
in general payments reported to CMS, 2019-2025
24 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.89 · 2022: $40.52 · 2024: $153 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $7,758 · Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,527.00 |
| Consulting Fee | $7,757.50 |
| Food and Beverage | $3,647.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $8,211.10 | 2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $5,002.44 | 2025 | |
| Tandem Diabetes Care, INC. | $3,941.71 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $3,497.07 | 2025 | Twiist |
| Genzyme Corporation | $2,574.59 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $120.18 | 2025 | Exparel |
| Lilly USA, LLC | $73.64 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $68.91 | 2025 | Tepezza, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.89 | 2019 | |
| Abbvie INC. | $62.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.07 | 2025 | Jardiance |
| Hologic Sales and Service, LLC | $48.02 | 2025 | Aptima |
| Novo Nordisk INC | $44.45 | 2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $39.19 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $38.06 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $37.30 | 2025 | Korlym |
| Radius Health, INC. | $24.63 | 2025 | |
| Madrigal Pharmaceuticals | $23.96 | 2025 | Rezdiffra |
| Ascensia Diabetes Care US INC. | $21.70 | 2025 | |
| Ibsa Pharma INC. | $20.43 | 2025 | Flector, Licart, Tirosint |
| Abbott Laboratories | $19.21 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $18.64 | 2025 | Unithroid |
| Medtronic, INC. | $16.98 | 2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $13.55 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Velez Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.